These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 25806348)

  • 1. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
    Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
    BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Xu Y; Ji H; Zhang Y; Xiong L; Han B; Zhong H; Xu J; Zhong R
    Oncologist; 2024 Jul; 29(7):e932-e940. PubMed ID: 38529688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
    Zhong W; Yang X; Yan H; Zhang X; Su J; Chen Z; Liao R; Nie Q; Dong S; Zhou Q; Yang J; Tu H; Wu YL
    J Hematol Oncol; 2015 May; 8():54. PubMed ID: 25981169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
    Yin Q; Xun X; Yang G; Cui H; Liu H
    Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study.
    Lv C; Ma Y; Feng Q; Lu F; Chi Y; Wu N; Fang J; Yang Y
    J Thorac Dis; 2020 Oct; 12(10):5324-5335. PubMed ID: 33209366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)
    Xiong L; Li R; Sun J; Lou Y; Zhang W; Bai H; Wang H; Shen J; Jing B; Shi C; Zhong H; Gu A; Jiang L; Shi J; Fang W; Zhao H; Zhang J; Wang J; Ye J; Han B
    Oncologist; 2019 Feb; 24(2):157-e64. PubMed ID: 30158288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials.
    Sun L; Guo YJ; Song J; Wang YR; Zhang SL; Huang LT; Zhao JZ; Jing W; Han CB; Ma JT
    Front Oncol; 2020; 10():586596. PubMed ID: 33511076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
    Zhong WZ; Yan HH; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang XZ; Yan WP; Liao RQ; Yang JJ; Zhang XC; Liu SY; Zhou Q; Wu YL
    Signal Transduct Target Ther; 2023 Feb; 8(1):76. PubMed ID: 36823150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN; Goss GD
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
    Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ
    World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study.
    Liu JF; Sun XS; Yin JH; Xu XE
    Front Oncol; 2023; 13():1132854. PubMed ID: 36994198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
    Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
    Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Have adjuvant tyrosine kinase inhibitors lost their shine?
    Sabari JK; Chaft JE
    Ann Transl Med; 2016 Aug; 4(15):285. PubMed ID: 27568486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.